Cardiovascular disease (CVD) stands as a formidable global health challenge, encompassing a spectrum of conditions including cardiomyopathy, coronary heart disease (CHD), hypertension, heart valve disease, arrhythmia, etc.71Recent research endeavours have illuminated RBFOX2's potential utility as a diagnostic and prognostic biomarker for CVDs, with mounting evidence linking its dysregulated expression to the onset of these diseases. This evidence concerns the gene RBFOX2 and cardiomyopathy.